Back

Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Novel biomarkers in acute and chronic coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Clinical validation of a point of care whole blood high sensitive cardiac troponin I assay: a prospective real time study on 3306 consecutive presentations with suspected acute coronary syndrome
Professor A. Khand (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Establishing reference values in healthy participants for a next generation cardiac troponin T high-sensitivity assay - the REF-TSIX global reference study
Professor L. Daniels (La Jolla, US)
Abstract Slides Video
Presentation thumbnail
Platelet-Derived-Growth-Factor-Receptor-beta (PDGFB) and atherosclerotic cardiovascular disease presentation in genetically diagnosed familial hypercholesterolemia
Doctor T. Padro (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
The use of biomarkers to identify and prognosticate patients with a type 2 myocardial infarction (T2MI): a systematic review
Doctor S. Lalani (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Association of dynamic changes in triglyceride-glucose index with lipid profiles and target attainments in coronary artery disease patients undergoing lipid-lowering therapy
Doctor Z. Li (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Novel biomarkers in acute and chronic coronary syndromes
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Lp(a) epidemiology and pathophysiology
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
thumbnail
Congress Presentation
Quick fire round Q&A

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources